Nuatigenin-type steroids, such as nuatigenin and isonuatigenin (9, 13, 22) , are rare natural steroidal sapogenins that are important pharmacological compounds. They are found in several healthy foods and traditional medicinal herbs. These compounds have been shown to have potential anticancer effects, antagonistic effects on rheumatoid arthritis, beneficial cardiovascular activities, and antimalarial activities. Examples include ophiofurospiside in Ophiopogon japonicus (28) , nuatigenosido in Solanum sisymbriifolium (13) , avenacoside in oat (20) , and glycosides in Paris polyphylla SM (7) . Since the majority of these nuatigenin-type steroids are very rare, strategies for their isolation can lead to very high production costs. As a result, with a more economical production process in mind, it would be worthwhile to search for a suitable reagent capable of converting the abundant amounts of pyrano-spirostanol sapogenins found in nature, such as diosgenone, to rare nuatigenintype steroids. At this time, we plan to focus on microbial transformation systems.
A previous article (25) described an actinomycete strain named Streptomyces virginiae IBL-14, isolated from soil, that can transform diosgenone to isonuatigenone by introducing a hydroxyl group to the tertiary C-25 atom of the F-ring (Fig. 1) . To our knowledge, this was the first report of producing a rare nuatigenin-type spiro steroid from diosgenone by microbial biotransformation. The present study was conducted in order to identify the determinant enzyme from S. virginiae IBL-14 that catalyzes the biotransformation and to design a whole-cell cytochrome P450 system to produce isonuatigenone by using Escherichia coli.
Initial attempts to clone the genetic determinant for the biocatalytical activity. Based on preliminary biochemical results suggesting that the catalytic enzyme in the IBL-14 strain is a cytochrome P450 monooxygenase (CYP), we attempted to isolate diverse CYP genes from S. virginiae IBL-14. The CYPencoding genes cyp10, cyp20, cyp24, cyp71, wbyA, and yxlB were isolated by PCR using degenerate primers (Table 1) designed to bind to the conserved oxygen-and heme-binding domains of CYPs (12, 14) . Four additional CYPs (expressed by cyp72, cyp73, cyp165, and fcpC) in this strain were also identified using high-stringency primers (Table 1 ) designed specifically against genes for CYPs that are related to the bioconversion of steroids and tertiary hydroxylations (4, 21) .
The fcpC gene product serves as the enzyme for the C-25 hydroxylation of diosgenone. To establish the in vivo function of the CYP gene products, we developed a genetic system in IBL-14 and disrupted each cyp gene by single-crossover homologous recombination. The inactivation of fcpC [to create the SCWF1 (⌬fcpC) mutant] by the insertion of PKC1139 (5, 27) , a temperature-sensitive plasmid containing an apramycin resistance gene, led to significant disruption in the production of isonuatigenone (Fig. 2, line b) .
A 0.8-kb fragment of fcpC was used as a probe against an IBL-14 subgenomic library in order to identify the full-length gene (Fig. 3) . fcpC encodes a peptide of 397 amino acids (with a molecular mass of 43.77 kDa) that belongs to the CYP105 family. The closest match in the databases to the deduced amino acid sequence is the sequence of a putative P450 monooxygenase encoded by a secondary-metabolite biosynthetic gene cluster in Kitasatospora putterlickiae (GenBank accession number DQ792514), sharing 65% identity with FcpC. The fcpD gene, downstream of fcpC in the genome, is considered to encode the native ferredoxin for FcpC. The start codon of fcpD is GTG instead of ATG, as in fcpC, and the first nucleotide of its initiation codon immediately precedes the stop codon of fcpC. In addition, a possible ribosome-binding site (GGGA) 6 nucleotides upstream of the initiation codon was found.
A complementation test for the fcpC disruption was conducted by introducing fcpCD (1.5 kb) under the control of a constitutively expressed ermE* promoter (26) . To this end, fcpCD was inserted into the plasmid pIB139 (creating pCFCP11, with a switch to kanamycin resistance) before conjugation into strain SCWF1. The diosgenone hydroxylation activity was restored in strain SCWF2 (SCWF1::pCFCP11) ( Fig. 2 , line c). These results clearly show that the enzyme FcpC is responsible for isonuatigenone production.
Conversion of diosgenone to isonuatigenone in vitro. The fcpC gene was amplified from genomic DNA using PCR with the following primers: 5Ј-GCCCCCcatatgAGTGAGTCCCTC CACACCGTC (where an NdeI recognition sequence is in lowercase and the start of the coding sequence of fcpC is underlined) and 5Ј-GGAGgaattcACTTCGCGTCCCAGG TGAC (where the sequence in lowercase is an EcoRI recognition site and the underlined sequence is the reverse complement of the fcpC translation stop codon and is followed by the 3Ј-end sequence of the fcpC gene). The resulting fcpC DNA fragment was digested with NdeI/EcoRI and ligated into a pET28 vector previously digested with NdeI/EcoRI (creating pFCP1). This strategy generated an N-terminally His 6 -tagged FcpC construct (2, 24) for further biochemical characterization. After Ni-nitrilotriacetic acid chromatography (14, 29) , the purified, red, recombinant P450 displayed (upon reduction) a signature peak at 450 nm in the CO difference spectrum (15, 19) . Following desalting, FcpC was dissolved in 100 mM K 2 HPO 4 -KH 2 PO 4 , pH 7.3. A typical reaction mixture consisted of 1.90 ml of protein (containing 50 to 100 g of FcpC), 3.5 M spinach ferredoxin (Sigma), and 0.1 U of ferredoxin-NADPH reductase (Sigma) in a total assay volume of 2.0 ml (6) . A total of 1 l of the diosgenone substrate (as a solution in isopropanol) was added to obtain final concentrations varying between 0.1 and 20 M. Following incubation at 30°C for 5 min, the reaction was started by the addition of NADPH to obtain a final concentration of 0.2 mM. The activity of the purified His-tagged FcpC was measured spectrophotometrically, following the consumption of NADPH at 340 nm and 30°C for 10 min (18) . The data were used to fit the LineweaverBurk equation (in Microsoft Excel) in order to determine the Our results indicate that FcpC has a K m of 2.4 Ϯ 0.8 M, a V max of 0.024 Ϯ 0.011 mol/min/mg, and a turnover number of 1.06 min Ϫ1 for diosgenone hydroxylation. In comparison, the well-characterized bacterial CYP enzyme EryF, which is responsible for the hydroxylation of 6-deoxyerythronolide B to form erythronolide B in Saccharopolyspora erythraea, shows a turnover number of 52.8 min Ϫ1 for its natural substrate (1, 23). Since diosgenone is not the natural substrate for FcpC, this artificial substrate may not interact very well with the active site, leading to the observed lower turnover number. In addition, because the diosgenone substrate is not soluble in water (diosgenone concentration, Ͻ20 M), it had to be dissolved in isopropanol in order to be added to the assay mixture. When the substrate solution was mixed with water, precipitation was observed immediately (diosgenone concentration, Ͼ60 M). Given these observations, it is possible that the substrate may not have formed a proper solution under our assay conditions.
Bioconversion of diosgenone by E. coli resting cells expressing fcpC and redox partners. CYPs are highly attractive biocatalysts due to their abilities to catalyze a variety of regio-and stereospecific oxidation reactions of complex organic compounds under mild conditions. This remarkable feat is accomplished by taking advantage of the two-electron activated dioxygen, which is often challenging in organic synthesis (10) . In order to activate molecular oxygen, a redox partner(s) is required to sequentially transfer two reducing equivalents from NAD(P)H to CYP (11) . This inherent requirement of cytochome P450 enzymes for protein partners significantly limits their application in biotechnology (16) .
FcpC belongs to the class I P450 system, in which electrons are transferred from NADH or NADPH to the enzyme via a flavin adenine dinucleotide-containing reductase (ferredoxin reductase) and an iron-sulfur protein (ferredoxin). FcpD is considered to be the native ferredoxin for FcpC; however, the gene encoding the native S. virginiae IBL-14 ferredoxin reductase has not yet been cloned. Instead, preliminary CO-reduced spectrum results (see Fig. S11 in the supplemental material) indicate that SC4B10, one of three ferredoxin reductases from Streptomyces coelicolor A3(2) (3, 15, 17) , helps increase the amount of active FcpC (11, 15, 16, 17) . We constructed an operon in pFCP1 consisting of three genes and one expression plasmid by cloning fcpD and the ferredoxin reductase SC4B10 gene downstream of fcpC (Fig. 4) . This new construct, pFCP2, was then expressed in E. coli BL21 Star(DE3)(pRARE).
After induction for 24 h with 0.2 mM IPTG (isopropyl-␤-Dthiogalactopyranoside) at 20°C, transformed E. coli cells were harvested by centrifugation and resuspended in reaction buffer containing 100 mM K 2 HPO 4 -KH 2 PO 4 and 1% (vol/vol) glycerol, pH 7.5. Following the addition of a 0.15% (vol/vol) solution of diosgenone in isopropanol (30 mg/ml), the reaction was allowed to proceed at 20°C, with shaking at 160 rpm. The level of conversion achieved a product yield exceeding 5% after 24 h of incubation (Fig. 2, d) .
The biotransformation of E. coli cells to express the complete electron transfer chain resulted in a 12-fold increase in the rate of isonuatigenone production compared to the rate obtained using an E. coli strain expressing only fcpC and fcpD (0.42%). As a control, all E. coli strains expressing only one of the three proteins of the electron transfer chain showed no substrate conversion. The increase in isonuatigenone production was mediated by the inclusion of ferredoxin and ferredoxin reductase, which together stabilize the P450 enzyme and provide an optimal electron transfer system (11, 15, 16, 17) .
In conclusion, compared to the traditional isolation strategy (9, 13, 22) , our whole-cell system using FcpC from S. virginiae IBL-14 expressed in E. coli can be a potentially valuable method for producing rare nuatigenin-type steroids. Our future work will focus on improving the present fcpC biotransformation system by using different hosts, promoters, vectors, and cloned redox partners for the extensive utilization of novel derivatives of steroidal drugs.
Nucleotide sequence accession number. The GenBank accession number for the fcpC and fcpD gene sequences identified in this study is EF646279.
